Ascend Wellness Q2 2026: Revenue $126.1M, Net Loss Narrows to $9.8M, Cash $67M
AAWH sits 22% above its 52-week low of $0.34.
Summary
Ascend Wellness reported Q2 2026 revenue of $126.1 million and a narrowed net loss of $9.8 million, with improved gross margins and a tax benefit from cannabis rescheduling. Cash fell to $67 million amid litigation and acquisition costs.
Key Events · Earnings and Guidance · AAWH
-
Q2 Revenue $126.1M, Net Loss Narrows
Revenue of $126.1 million was down 1% year-over-year but up 7.9% sequentially. Net loss improved to $9.8 million from $24.4 million a year ago, driven by higher gross margin (36.1% vs 32.5%) and a $14.8 million tax benefit.
-
Cash Declines to $67M
Cash and cash equivalents fell to $67 million from $85.7 million at year-end, reflecting $17 million in litigation settlement payments, acquisition spending, and capital expenditures. Management states cash is adequate for the next twelve months.
-
Tax Benefit from Cannabis Rescheduling
The April 2026 DOJ order rescheduling medical cannabis to Schedule III allowed the company to recognize IRC Section 280E relief and release $14.8 million from uncertain tax positions, favorably impacting the effective tax rate.
-
Acquisitions Expand Retail Footprint
The company recognized business combinations for Northeast Partnership Dispensaries Seven and Eight ($3.6M) and Midwest Partnership Two Dispensaries ($22.3M), adding six adult-use dispensaries subject to regulatory approval.
Analysis · AAWH · Life Sciences
Ascend Wellness reported Q2 2026 revenue of $126.1 million, down 1% year-over-year but up 7.9% sequentially, with gross margin improving to 36.1% from 32.5%. Net loss narrowed to $9.8 million from $24.4 million a year ago, helped by a $14.8 million release from uncertain tax positions following the April 2026 federal rescheduling of medical cannabis to Schedule III. Cash declined to $67 million from $85.7 million at year-end, driven by $17 million in litigation settlement payments and acquisition spending. The company faces a $300 million term note maturity in 2029 and an upcoming shareholder vote on a reverse stock split on August 28.
At the time of this filing, AAWH was trading at $0.42 on OTC in the Life Sciences sector, with a market capitalization of approximately $84.3M. The 52-week trading range was $0.34 to $1.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.